期刊文献+

HGF通过AKT信号通路对胃癌淋巴管生成的作用 被引量:1

下载PDF
导出
摘要 胃癌是常见的消化道恶性肿瘤,具有发病率高、死亡率高的特点。全世界胃癌的发病率在恶性肿瘤中排名第4位,死亡率排名第2位,而在我国,胃癌的发病率及死亡率均占恶性肿瘤的第3位[1]。随着诊疗技术的进展,目前早期胃癌可以通过外科手术及在内镜下治疗得到缓解。然而,多数胃癌在明确诊断时已经扩散、转移。其中淋巴转移是胃癌最主要的扩散途径,是胃癌患者重要的预后指标之一。
作者 王可 李国庆
出处 《现代医药卫生》 2016年第24期3814-3816,共3页 Journal of Modern Medicine & Health
  • 相关文献

参考文献3

二级参考文献121

  • 1肖琳,唐良萏.肝细胞生长因子及其受体在子宫内膜癌组织中的表达及其意义[J].重庆医科大学学报,2004,29(6):789-791. 被引量:4
  • 2Yi-LingLi,ZhongTian,Dong-YingWu,Bao-YuFu,YahXin.Loss of heterozygosity on 10q23.3 and mutation of tumor suppressor gene PTEN in gastric cancer and precancerous lesions[J].World Journal of Gastroenterology,2005,11(2):285-288. 被引量:34
  • 3刘爱东,王献华,庞久玲.大肠癌血管内皮生长因子-C及酪氨酸激酶受体-4的表达与淋巴管生成及其转移的关系[J].华北煤炭医学院学报,2006,8(5):592-594. 被引量:14
  • 4Kajiya K,Hirakawa S,Ma B,et al.Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO Journal . 2005
  • 5Wei-Tien Tai,Ann-Lii Cheng,Chung-Wai Shiau,Hsiang-Po Huang,Jui-Wen Huang,Pei-Jer Chen,Kuen-Feng Chen.Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma[J].Journal of Hepatology.2011(5)
  • 6George R. Blumenschein,Gordon B. Mills,Ana M. Gonzalez-Angulo.Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy[J].Journal of Clinical Oncology.2012(26)
  • 7Yoon-Koo Kang,Kei Muro,Min-Hee Ryu,Hirofumi Yasui,Tomohiro Nishina,Baek-Yeol Ryoo,Yukimasa Kamiya,Shiro Akinaga,Narikazu Boku.A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer[J].Investigational New Drugs.2014(2)
  • 8Andrew S Giraud,Trevelyan R Menheniott,Louise M Judd.Targeting STAT3 in gastric cancer[J].Expert Opinion on Therapeutic Targets.2012(9)
  • 9Brendan D. Manning,Lewis C. Cantley.AKT/PKB Signaling: Navigating Downstream[J].Cell.2007(7)
  • 10Timothy Iveson,Ross C Donehower,Irina Davidenko,Sergey Tjulandin,Andrzej Deptala,Mark Harrison,Somanath Nirni,Kuntegowdanahalli Lakshmaiah,Anne Thomas,Yizhou Jiang,Min Zhu,Rui Tang,Abraham Anderson,Sarita Dubey,Kelly S Oliner,Elwyn Loh.Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study[J]. Lancet Oncology . 2014 (9)

共引文献23

同被引文献16

引证文献1

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部